Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, multicenter, randomized, double-blind, pilot study to evaluate the safety, the efficacy, the tolerability, and the emergence of resistant gram-negative microorganisms in the bowel in elderly patients with serious community-acquired bacterial pneumonia treated with a short regimen fo ertapenem versus high-dose levofloxacin.

Trial Profile

A prospective, multicenter, randomized, double-blind, pilot study to evaluate the safety, the efficacy, the tolerability, and the emergence of resistant gram-negative microorganisms in the bowel in elderly patients with serious community-acquired bacterial pneumonia treated with a short regimen fo ertapenem versus high-dose levofloxacin.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ertapenem (Primary) ; Levofloxacin
  • Indications Community-acquired pneumonia; Gram-negative infections
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme

Most Recent Events

  • 14 Apr 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top